PDS Biotechnology (NASDAQ:PDSB) Issues Quarterly Earnings Results

PDS Biotechnology (NASDAQ:PDSB) released its earnings results on Thursday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05), FiscalAI reports.

PDS Biotechnology Stock Performance

Shares of PDS Biotechnology stock traded down $0.01 during trading on Thursday, hitting $0.23. 4,339,664 shares of the company’s stock were exchanged, compared to its average volume of 958,785. The stock has a market capitalization of $13.04 million, a price-to-earnings ratio of -0.35 and a beta of 1.62. PDS Biotechnology has a 52-week low of $0.22 and a 52-week high of $1.55. The business has a 50-day simple moving average of $0.82 and a 200-day simple moving average of $0.86. The company has a debt-to-equity ratio of 2.73, a quick ratio of 2.26 and a current ratio of 2.26.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of PDS Biotechnology in a research note on Wednesday, April 15th. Finally, Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.00.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PDSB. Armistice Capital LLC acquired a new position in PDS Biotechnology during the fourth quarter worth $2,182,000. Squarepoint Ops LLC boosted its holdings in shares of PDS Biotechnology by 116.1% during the 3rd quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after purchasing an additional 156,662 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in PDS Biotechnology by 117.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after buying an additional 106,300 shares in the last quarter. Susquehanna International Group LLP grew its holdings in shares of PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after purchasing an additional 80,937 shares during the period. Finally, Jane Street Group LLC purchased a new position in PDS Biotechnology during the second quarter worth about $92,000. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.